Impact News +++ Wirksamkeit nicht vergleichbar?: Curevac-Chef verteidigt maue Testergebnisse (N-TV) +++ CUREVAC Aktie -3,15%

BIOGEN Aktie

 >BIOGEN Aktienkurs 
323.80 EUR    +0.5%    (Tradegate)
Ask: 323.70 EUR / 35 Stück
Bid: 322.10 EUR / 35 Stück
Tagesumsatz: 3 Stück
Realtime Kurs von 8 bis 22 Uhr!
>BIOGEN Performance
1 Woche: -5,1%
1 Monat: +40,2%
3 Monate: +47,5%
6 Monate: +59,1%
1 Jahr: +28,3%
laufendes Jahr: +62,8%
>BIOGEN Aktie
Name:  BIOGEN INC. DL -,0005
Land:  USA
Sektor:  Gesundheit
ISIN/ Wkn:  US09062X1037 / 789617
Symbol/ Ticker:  IDP (Frankfurt) / BIIB (NASDAQ)
Kürzel:  FRA:IDP, IDP.F, IDP:GR, NASDAQ:BIIB
Index:  S&P500, Nasdaq100
Webseite:  https://www.biogen.com/
Marktkapitalisierung:  49740 Mio. EUR
Umsatz:  10479.22 Mio. EUR
EBITDA:  3443.17 Mio. EUR
Gewinn je Aktie:  13.232 EUR
Schulden:  6362.38 Mio. EUR
Liquide Mittel:  2112.48 Mio. EUR
Umsatz-/ Gewinnwachstum:  -23.8% / -70.7%
KGV/ KGV lG:  20.76 / 18.91
KUV/ KBV/ PEG:  3.95 / 4.66 / -1.9
Gewinnm./ Eigenkapitalr.:  23.89% / 26.49%
Dividende je Aktie:  -
Dividendenrendite/ -schätzung:  - / -
Insiderhandel:  3 Insider verkauften innerhalb der letzten 30 Tage Aktien im Wert von 4.832.661 USD.
Suchwörter:  BIOGEN
Letzte Datenerhebung:  16.06.21
>BIOGEN Eigentümer
Aktien: 150.56 Mio. St.
f.h. Aktien: 149.52 Mio. St.
Insider Eigner: 0.65%
Instit. Eigner: 87.08%
Leerverk. Aktien: 2.34%
 >BIOGEN Anleihen 
Es sind 2 Anleihen zur BIOGEN Aktie bekannt.
>BIOGEN Peer Group

 
18.06.21 - 01:33
Biogen′s Alzheimer′s Drug Approval Puts Biotech ETFs in Spotlight (Zacks)
 
The FDA's approval of the first new drug to treat Alzheimer's disease in about 20 years has attracted investors' attention toward the biotech sector while sparking new controversies....
17.06.21 - 20:18
Biogen: 5 Key Questions (And Answers) For Investors Following Aduhelm Approval (SeekingAlpha)
 
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...
17.06.21 - 16:33
Biogen (BIIB) Ends Development of Anti-Tau Alzheimer′s Drug (Zacks)
 
Biogen (BIIB) ends development of investigational anti-tau antibody, gosuranemab for treating Alzheimer's disease after the phase II TANGO study showed no benefit to patients....
17.06.21 - 15:43
Thinking about trading options or stock in Prothena Corp, CureVac, Centene Corp, AMC, or Biogen? (PR Newswire)
 
NEW YORK, June 17, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for PRTA, CVAC, CNC, AMC, and BIIB. Click a link below then choose between in-depth options trade idea report or a stock score report. Options Report – Idea...
17.06.21 - 14:39
The Daily Biotech Pulse: Biogen Faces Another Clinical Setback, CureVac′s COVID-19 Vaccine Study Fails, Moment Of Reckoning For Orphazyme (Benzinga)
 
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 16) read more...
17.06.21 - 13:42
Biogen starts dosing in late-stage systemic lupus erythematosus study (SeekingAlpha)
 
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...
17.06.21 - 13:33
Biogen Announces First Patient Dosed in Phase 3 Systemic Lupus Erythematosus Study (GlobeNewswire EN)
 
CAMBRIDGE, Mass., June 17, 2021 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced that the first patient has been dosed in the global clinical study, TOPAZ-1. The Phase 3 study will evaluate the clinical efficacy and assess the safety ...
17.06.21 - 13:00
Biogen Discontinues Tau Antibody Program For Alzheimer′s After Mid-Stage Study Flops (Benzinga)
 
Biogen Inc (NASDAQ: BIIB) has four other Alzheimer's candidates in its clinical pipeline behind recently-approved Aduhelm, of which one has just been canned. read more...
16.06.21 - 23:49
First Patient Receives Biogen′s Alzheimer′s Drug Aduhelm (AFX)
 
WESTON (dpa-AFX) - Marc Archambault, a 70-year old man from Rhode Island, has become the first patient to receive Biogen Inc's (BIIB) newly approved and controversial Alzheimer's drug Aduhelm outs......
16.06.21 - 23:04
Biogen halts development of antibody drug aimed at Alzheimer’s (MarketWatch)
 
Shares of Biogen Inc. fell nearly 1% in the extended session after the pharma company said it will halt the development of an antibody drug aimed at treating Alzheimer's disease after a study showed no benefit to patients.......
16.06.21 - 22:48
Biogen hurt by setback in mid-stage Alzheimer’s trial for anti-tau antibody (SeekingAlpha)
 
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...
16.06.21 - 22:33
Biogen Announces Topline Results From Phase 2 Study of Gosuranemab, an Anti-Tau Antibody, for Alzheimer′s Disease (GlobeNewswire EN)
 
CAMBRIDGE, Mass., June 16, 2021 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced topline results from its Phase 2 TANGO study of gosuranemab (BIIB092), an investigational anti-tau antibody that was being evaluated as a potential trea...
16.06.21 - 19:48
Patient receives first infusion of Biogens controversial Alzheimers drug (CNBC)
 
A 70-year-old man from Rhode Island on Wednesday was the first to receive an infusion outside of a clinical trial of Biogen's Alzheimer's drug, Aduhelm....
16.06.21 - 18:26
UPDATE 1-First patient receives controversial Biogen Alzheimer′s drug (Reuters EN)
 
... Beasley June 16 (Reuters) - A U.S. hospital on Wednesday gave the first... School neurology professor Dr. Stephen Salloway told Reuters. He said......
16.06.21 - 17:06
FDA officials should resign over ′reckless′ approval of Biogen Alzheimer′s drug, says US consumer rights group (Proactive Investors)
 
A US consumer rights group has said the acting commissioner of the Food and Drug Administration (FDA) Janet Woodcock and other officials should “immediately resign” over the regulator's approval of Biogen Inc's (NASDAQ:BIIB) controversial Alzh...
16.06.21 - 16:48
Public Citizen demands removal of top FDA officials over Biogen Alzheimer′s approval (SeekingAlpha)
 
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...
16.06.21 - 16:23
Biogen's FDA Win Marks a Mini-Rally in Biotech Stocks (MarketWatch)
 
Biotech stocks are surging in June on a raft of upbeat news from Biogen. It's a turnaround from a spring drubbing....
16.06.21 - 15:02
Notenbank: Mehr Taube als Falke? Und Oracle, Roblox, Amazon, Biogen, NVIDIA. (Markus Koch)
 
Um den gesamten Artikel unter youtube.com zu lesen, klicken Sie bitte auf die Überschrift...
>Zitat des Tages: Hungriges Pferd macht die Krippe sauber. - Sprichwort Frankreich
Partner:    >Tradegate Börse | >TraderFox Handelssignale | >Heibel-Ticker Börsenbrief | >Dukascopy | >Boersentreff- Partner

Börsentreff auf Facebook | Börsentreff auf Twitter | Börsentreff auf Instagram

Copyright @ Boersentreff.de - Die Märkte im Blick!